FDANews
FDAnews Device Daily Bulletin

INVO Bioscience’s Phase IV Trial of INVOcell Yields Positive Results

Feb. 25, 2016

Medford, Mass.-based INVO Bioscience saw positive results in a Phase 4 trial when comparing the INVOcell intravaginal culture system to traditional IVF incubation in relation to embryo quality and live birth rates.

The results demonstrated that INVOcell has comparable live birth rates to traditional IVF incubation, according to Kevin Doody, founder of the Centre for Assisted Reproduction and INVO Bioscience.

Benefits include stable vaginal incubation, lower costs for fertility procedures and increased access. — Anisa Jibrell